

FLURAZEPAM HYDROCHLORIDE- flurazepam hydrochloride capsule

Chartwell RX, LLC

HIGHLIGHTS OF PRESCRIBING INFORMATION

Flurazepam Hydrochloride Capsules, USP

These highlights do not include all the information needed to use FLURAZEPAM HYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for FLURAZEPAM HYDROCHLORIDE CAPSULES.

FLURAZEPAM HYDROCHLORIDE capsules, for oral use CIV
Initial U.S. Approval: 1970

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

See full prescribing information for complete boxed warning.

- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (5.1, 7.1).
- The use of benzodiazepines, including flurazepam hydrochloride capsules, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing flurazepam hydrochloride capsules and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (5.2).
- Abrupt discontinuation or rapid dosage reduction of flurazepam hydrochloride capsules after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue flurazepam hydrochloride capsules or reduce the dosage (2.3, 5.3).

INDICATIONS AND USAGE

Flurazepam, a gamma-aminobutyric (GABA_A) agonist, is indicated for the treatment of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. (1)

DOSAGE AND ADMINISTRATION

- Use the lowest dose effective for the patient.
- Recommended initial dose is 15 mg for women and 15 mg or 30 mg for men. (2.1)
- Elderly or debilitated patients: recommended dose is 15 mg. (2.2)

DOSAGE FORMS AND STRENGTHS

- 15 mg and 30 mg capsules. (3)

CONTRAINDICATIONS

- Hypersensitivity to flurazepam or other benzodiazepines. (4)

WARNINGS AND PRECAUTIONS

- CNS depressant effects: Impaired alertness and motor coordination, including risk of falling. Daytime impairment. Caution patients against driving and other activities requiring complete mental alertness. (5.4)
- The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. (5.5)
- Severe anaphylactic/anaphylactoid reactions: Angioedema and anaphylaxis have been reported. Do not rechallenge if such reactions occur. (5.6)
- Sleep driving and other complex behaviors while not fully awake: Risk increases with dose and concomitant CNS depressants and alcohol. Immediately evaluate any new onset behavioral changes. (5.7)

- Worsening of depression or suicidal thinking may occur: Prescribe the least number of capsules feasible to avoid intentional overdose. (5.8)
- Neonatal Sedation and Withdrawal Syndrome: Flurazepam use during pregnancy can result in neonatal sedation and/or neonatal withdrawal. (5.9)

-----ADVERSE REACTIONS-----

Adverse reactions: dizziness, drowsiness, light-headedness, staggering, ataxia, falling. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Chartwell RX, LLC. at 1-845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-----DRUG INTERACTIONS-----

- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, and death. (7.1)
- CNS Depressants: Downward dose adjustment may be necessary due to additive effects. (7.2)

-----USE IN SPECIFIC POPULATIONS-----

- Lactation: Breastfeeding not recommended. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 12/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adults

2.2 Dosage in Elderly or Debilitated Patients

2.3 Discontinuation or Dosage Reduction of Flurazepam Hydrochloride Capsules

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Risks from Concomitant Use of Opioids

5.2 Abuse, Misuse, and Addiction

5.3 Dependence and Withdrawal Reactions

5.4 CNS-Depressant Effects and Next-Day Impairment

5.5 Need to Evaluate for Co-morbid Disorders

5.6 Severe Anaphylactic or Anaphylactoid Reactions

5.7 Abnormal Thinking and Behavior Changes

5.8 Worsening of Depression

5.9 Neonatal Sedation and Withdrawal Syndrome

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

7 DRUG INTERACTIONS

7.1 Opioids

7.2 CNS Depressants

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

9.2 Abuse

9.3 Dependence

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see *Warnings and Precautions* (5.1) and *Drug Interactions* (7.1)].
- The use of benzodiazepines, including flurazepam hydrochloride capsules, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing flurazepam hydrochloride capsules, and throughout treatment, assess each patient's risk for abuse, misuse, and addiction [see *Warnings and Precautions* (5.2)].
- The continued use of benzodiazepines, including flurazepam hydrochloride capsules, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of flurazepam hydrochloride capsules after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue flurazepam hydrochloride capsules or reduce the dosage [see *Dosage and Administration* (2.3) and *Warnings and Precautions* (5.3)].

1 INDICATIONS AND USAGE

Flurazepam hydrochloride capsules are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings [see *Clinical Studies* (14)].

Since insomnia is often transient and intermittent, short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage in Adults

Use the lowest dose effective for the patient, as important adverse effects of flurazepam hydrochloride capsules are dose related.

The recommended initial dose is 15 mg for women and either 15 mg or 30 mg for men.

The 15 mg dose can be increased to 30 mg if necessary for efficacy.

The recommended initial doses for women and men are different because flurazepam clearance is lower in women [see *Pharmacokinetics* (12.3)].

2.2 Dosage in Elderly or Debilitated Patients

Elderly or debilitated patients may be especially sensitive to flurazepam. Since the risk of the development of oversedation, dizziness, confusion and/or ataxia increases substantially with larger doses in elderly or debilitated patients, it is recommended that in such patients the dosage be limited to 15 mg. Staggering and falling have also been reported, particularly in geriatric patients [see *Warnings and Precautions* (5.2)].

2.3 Discontinuation or Dosage Reduction of Flurazepam Hydrochloride Capsules

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue flurazepam hydrochloride capsules or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly [see *Warnings and Precautions* (5.3) and *Drug Abuse and Dependence* (9.3)].

3 DOSAGE FORMS AND STRENGTHS

Flurazepam Hydrochloride Capsules, USP are available containing either 15 mg or 30 mg of Flurazepam Hydrochloride, USP.

Flurazepam Hydrochloride Capsules, USP 15 mg are Size #2 hard gelatin capsules, Blue opaque cap with white opaque body, imprinted with “ **CE**” on the cap and “ **28**” on the body with black ink, filled with white to off-white powder.

Flurazepam Hydrochloride Capsules, USP 30 mg are Size #2 hard gelatin capsules, Blue opaque cap with white opaque body, imprinted with “ **CE**” on the cap and “ **29**” on the body with black ink, filled with white to off-white powder.

4 CONTRAINDICATIONS

Flurazepam hydrochloride capsules are contraindicated in patients with known hypersensitivity to flurazepam or other benzodiazepines. Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of flurazepam. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis. Patients who develop such reactions should not be rechallenged with flurazepam.

5 WARNINGS AND PRECAUTIONS

5.1 Risks from Concomitant Use of Opioids

Concomitant use of benzodiazepines, including flurazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids in patients for whom

alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe flurazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when flurazepam is used with *opioids* [see *Drug Interactions* (7)].

5.2 Abuse, Misuse, and Addiction

The use of benzodiazepines, including flurazepam hydrochloride capsules, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see *Drug Abuse and Dependence* (9.2)].

Before prescribing flurazepam hydrochloride capsules and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of flurazepam hydrochloride capsules, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of flurazepam hydrochloride capsules along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.

5.3 Dependence and Withdrawal Reactions

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue flurazepam hydrochloride capsules or reduce the dosage (a patient-specific plan should be used to taper the dose) [see *Dosage and Administration* (2.3)] . Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use.

Acute Withdrawal Reactions: The continued use of benzodiazepines, including flurazepam hydrochloride capsules, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of flurazepam hydrochloride capsules after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see *Drug Abuse and Dependence* (9.3)].

Protracted Withdrawal Syndrome: In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months [see *Drug Abuse and Dependence* (9.3)].

5.4 CNS-Depressant Effects and Next-Day Impairment

Dizziness, drowsiness, light-headedness, staggering, ataxia and falling can occur, particularly in elderly or debilitated persons. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdosage, have been reported.

Flurazepam is a central nervous system (CNS) depressant and can impair daytime function even when used as prescribed. Prescribers should monitor for excess depressant effects, but impairment can occur in the absence of subjective symptoms, and may not be reliably detected by ordinary clinical exam (i.e., less than formal psychomotor testing). While pharmacodynamic tolerance or adaptation to some adverse depressant effects of flurazepam may develop, patients using flurazepam should be cautioned against driving or engaging in other hazardous activities or activities requiring complete mental alertness.

Additive effects occur with concomitant use of other CNS depressants (e.g., other benzodiazepines, opioids, tricyclic antidepressants, alcohol). Downward dose adjustment of flurazepam and concomitant CNS depressants should be considered. The potential for adverse drug interactions continues for several days following discontinuation of flurazepam, until serum levels of psychoactive metabolites decline.

Use of flurazepam with other sedative-hypnotics is not recommended. Alcohol generally should not be used during treatment with flurazepam. The risk of next-day psychomotor impairment is increased if flurazepam is taken with less than a full night of sleep remaining (7 to 8 hours); if higher than the recommended dose is taken; if coadministered with other CNS depressants [*see Dosage and Administration (2)*].

Because flurazepam can cause drowsiness and a decreased level of consciousness, patients, particularly the elderly, are at higher risk of falls.

5.5 Need to Evaluate for Co-morbid Disorders

Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative-hypnotic drugs.

5.6 Severe Anaphylactic or Anaphylactoid Reactions

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including flurazepam. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis.

Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with flurazepam should not be rechallenged with the drug.

5.7 Abnormal Thinking and Behavior Changes

Abnormal thinking and behavior changes have been reported in patients treated with

sedative-hypnotics including flurazepam. Some of these changes include decreased inhibition (e.g., aggressiveness and extroversion that seemed out of character), bizarre behavior, and depersonalization. Visual and auditory hallucinations have also been reported. Amnesia, and other neuro-psychiatric symptoms, may occur.

Paradoxical reactions such as stimulation, agitation, increased muscle spasticity, and sleep disturbances may occur unpredictably.

Complex behaviors such as “sleep-driving” (i.e., driving while not fully awake, with amnesia for the event) have been reported with use of sedative-hypnotics. These behaviors can occur with initial treatment or in patients previously tolerant of flurazepam or other sedative-hypnotics. Although these behaviors can occur with use at therapeutic doses, risk is increased by higher doses or concomitant use of alcohol or other CNS depressants. Due to risk to the patient and community, flurazepam should be discontinued if “sleep-driving” occurs.

Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.

5.8 Worsening of Depression

Benzodiazepines may worsen depression. Consequently, appropriate precautions (e.g., limiting the total prescription size and increased monitoring for suicidal ideation) should be considered.

5.9 Neonatal Sedation and Withdrawal Syndrome

Use of flurazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate [see *Use in Specific Populations (8.1)*]. Monitor neonates exposed to flurazepam during pregnancy or labor for signs of sedation and monitor neonates exposed to flurazepam during pregnancy for signs of withdrawal; manage these neonates accordingly.

6 ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the label:

- Risks from Concomitant Use with Opioids [see *Warnings and Precautions (5.1)*]
- Abuse, Misuse, and Addiction [see *Warnings and Precautions (5.2)*]
- Dependence and Withdrawal Reactions [see *Warnings and Precautions (5.3)*]
- CNS-depressant effects and next-day impairment [see *Warnings and Precautions (5.4)*]
- Severe Anaphylactic and Anaphylactoid Reactions [see *Warnings and Precautions (5.6)*]
- Abnormal thinking and behavior changes, and complex behaviors [see *Warnings and Precautions (5.7)*]
- Worsening of depression [see *Warnings and Precautions (5.8)*]
- Neonatal Sedation and Withdrawal Syndrome [see *Warnings and Precautions (5.9)*]

6.1 Clinical Trials Experience

Reported were headache, heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, gastrointestinal pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains, and genitourinary complaints. There have also been rare occurrences of leukopenia, granulocytopenia, sweating, flushes, difficulty in focusing, blurred vision, burning eyes, faintness, hypotension, shortness of breath, pruritus, skin rash, dry mouth, bitter taste, excessive salivation, anorexia, euphoria, depression, slurred speech, confusion, restlessness, hallucinations and elevated SGOT, SGPT, total and direct bilirubin elevations, and elevated alkaline phosphatase.

7 DRUG INTERACTIONS

7.1 Opioids

The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA_A sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation.

7.2 CNS Depressants

Benzodiazepines, including flurazepam, produce additive CNS depressant effects when co-administered with ethanol or other CNS depressants (e.g., psychotropic medications, anticonvulsants, antihistamines). Downward dose adjustment of flurazepam and/or concomitant CNS depressants may be necessary because of additive effects.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry:

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including flurazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or visiting online at <https://womensmentalhealth.org/pregnancyregistry/>.

Risk Summary

Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see *Warnings and Precautions* (5.9) and *Clinical Considerations*]. Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see *Data*).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other

adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation in neonates. Monitor neonates exposed to flurazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to HALCION during pregnancy for signs of withdrawal. Manage these neonates accordingly [see *Warnings and Precautions* (5.9)].

Data

Human Data

Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings.

Animal Data

Administration of flurazepam to pregnant animals did not indicate a risk for adverse effects on morphological development at clinically relevant doses; however, animal data for other benzodiazepines suggest that possibility of adverse developmental effects (including long-term effects on neurobehavioral and immunological function) following prenatal exposure.

8.2 Lactation

Risk Summary

There are no data on the presence of flurazepam in human or animal milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of flurazepam on milk production are unknown. Because of the flurazepam's long half-life, the potential for flurazepam to accumulate in breast milk, and the potential for serious adverse reactions, including sedation and withdrawal symptoms in breastfed infants, advise patients that breastfeeding is not recommended during treatment with flurazepam.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

Flurazepam may cause confusion and over-sedation in the elderly. Elderly patients generally should be started on a low dose of flurazepam and observed closely.

Elderly or debilitated patients may be more sensitive to benzodiazepines, reflecting the

greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Flurazepam is a Schedule IV controlled substance.

9.2 Abuse

Flurazepam hydrochloride capsules are a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse may lead to addiction.

Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders [*see Warnings and Precautions (5.2)*] .

The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo.

The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol) .

9.3 Dependence

Physical Dependence: Flurazepam hydrochloride capsules may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine

discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use [*see Warnings and Precautions (5.3)*].

To reduce the risk of withdrawal reactions, use a gradual taper to discontinue flurazepam hydrochloride capsules or reduce the dosage [*see Dosage and Administration (2.3) and Warnings and Precautions (5.3)*].

Acute Withdrawal Signs and Symptoms: Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality.

Protracted Withdrawal Syndrome: Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months .As a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used.

Tolerance: Tolerance to flurazepam hydrochloride capsules may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of flurazepam hydrochloride capsules may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

10 OVERDOSAGE

Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal [*see Warnings and Precautions (5.2)*] . Markedly abnormal (lowered or elevated) blood pressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage.


In managing benzodiazepine overdosage, employ general supportive measures, including intravenous fluids and airway management. Flumazenil, a specific benzodiazepine receptor antagonist indicated for the complete or partial reversal of the

sedative effects of benzodiazepines in the management of benzodiazepine overdose, can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdose with drugs that increase seizure risk (e.g., tricyclic and tetracyclic antidepressants) and in patients with long-term benzodiazepine use and physical dependency. The risk of withdrawal seizures with flumazenil use may be increased in patients with epilepsy. Flumazenil is contraindicated in patients who have received a benzodiazepine for control of a potentially life-threatening condition (e.g., status epilepticus). If the decision is made to use flumazenil, it should be used as an adjunct to, not as a substitute for, supportive management of benzodiazepine overdose. See the flumazenil injection Prescribing Information.

Consider contacting a poison center (1-800-222-1222), poisoncontrol.org, or a medical toxicologist for additional overdose management recommendations.

11 DESCRIPTION

Flurazepam Hydrochloride, USP is chemically 7-chloro-1-[2-(diethylamino)ethyl]-5-(*o*-fluoro-phenyl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one dihydrochloride. It is a pale yellow, crystalline compound, freely soluble in alcohol and very soluble in water. It has a molecular weight of 460.81 and the following structural formula:



Each capsule, for oral administration, contains either 15 mg or 30 mg of Flurazepam Hydrochloride, USP. In addition, each capsule contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, FD&C Blue #1, FD&C Red #3, gelatin, mannitol, magnesium stearate, talc, and titanium dioxide.

Additionally, capsule shells of 15 mg and 30 mg are imprinted with black pharmaceutical ink. The compositions of the black pharmaceutical ink are black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Flurazepam, like other central nervous system agents of the 1,4-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS). The exact mechanism of action is unknown.

12.3 Pharmacokinetics

Flurazepam hydrochloride is rapidly absorbed from the gastro-intestinal tract. Flurazepam is rapidly metabolized and is excreted primarily in the urine. Following a single oral dose, peak flurazepam plasma concentrations ranging from 0.5 to 4.0 ng/mL occur at 30 to 60 minutes post-dosing. The harmonic mean apparent half-life of flurazepam is 2.3 hours. The blood level profile of flurazepam and its major metabolites was determined in man following the oral administration of 30 mg daily for 2 weeks. The N1-hydroxyethyl-flurazepam was measurable only during the early hours after a 30 mg dose and was not detectable after 24 hours. The major metabolite in blood was N1-desalkyl-flurazepam, which reached steady-state (plateau) levels after 7 to 10 days of dosing, at levels approximately 5- to 6-fold greater than the 24-hour levels observed on Day 1. The half-life of elimination of N1-desalkyl-flurazepam ranged from 47 to 100 hours. The major urinary metabolite is conjugated N1-hydroxyethyl-flurazepam which accounts for 22% to 55% of the dose. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.

This pharmacokinetic profile may be responsible for the clinical observation that flurazepam is increasingly effective on the second or third night of consecutive use and that for 1 or 2 nights after the drug is discontinued both sleep latency and total wake time may still be decreased.

The single dose pharmacokinetics of flurazepam were studied in 12 healthy geriatric subjects (aged 61 to 85 years). The mean elimination half-life of desalkyl-flurazepam was longer in elderly male subjects (160 hours) compared with younger male subjects (74 hours), while mean elimination half-life was similar in geriatric female subjects (120 hours) and younger female subjects (90 hours). After multiple dosing, mean steady-state plasma levels of desalkyl-flurazepam were higher in elderly male subjects (81 ng/mL) compared with younger male subjects (53 ng/mL), while values were similar between elderly female subjects (85 ng/mL) and younger female subjects (86 ng/mL). The mean washout half-life of desalkyl-flurazepam was longer in elderly male and female subjects (126 and 158 hours, respectively) compared with younger male and female subjects (111 and 113 hours, respectively). ¹

¹Greenblatt DJ, Divoll M, Hammatz JS, MacLaughlin DS, Shader RI: Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 30: 475-486, 1981.

13 NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies to assess the genotoxic or carcinogenic potential of flurazepam or the effects of flurazepam on fertility have not been conducted.

14 CLINICAL STUDIES

Sleep laboratory studies have objectively determined that flurazepam hydrochloride capsules are effective for at least 28 consecutive nights of drug administration.

16 HOW SUPPLIED/STORAGE AND HANDLING

Flurazepam Hydrochloride Capsules, USP are available containing either 15 mg or 30 mg of Flurazepam Hydrochloride, USP.

Flurazepam Hydrochloride Capsules, USP 15 mg are Size #2 hard gelatin capsules, Blue opaque cap with white opaque body, imprinted with “ **CE**” on the cap and “ **28**” on the body with black ink, filled with white to off-white powder.

They are available as follows,

Bottle of 30's - NDC 62135-736-30

Bottle of 90's - NDC 62135-736-90

Flurazepam Hydrochloride Capsules, USP 30 mg are Size #2 hard gelatin capsules, Blue opaque cap with white opaque body, imprinted with “ **CE**” on the cap and “ **29**” on the body with black ink, filled with white to off-white powder.

They are available as follows,

Bottle of 30's - NDC 62135-737-30

Bottle of 90's - NDC 62135-737-90

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Protect from light and moisture.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

PHARMACIST:Dispense a Medication Guide with each prescription.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the *FDA-approved patient labeling (Medication Guide)*.

Risks from Concomitant Use with Opioids:Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when flurazepam hydrochloride capsules are used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider [see *Warnings and Precautions (5.1)*, *Drug Interactions (7.1)*].

Abuse, Misuse, and Addiction:Inform patients that the use of flurazepam hydrochloride capsules, even at recommended dosages, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances .Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug [see *Warnings and Precautions (5.2)* and *Drug Abuse and Dependence (9.2)*].

Withdrawal Reactions:Inform patients that the continued use of flurazepam hydrochloride capsules may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of flurazepam hydrochloride capsules may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of flurazepam

hydrochloride capsules may require a slow taper [see *Warnings and Precautions* (5.3) and *Drug Abuse and Dependence* (9.3)].

CNS Depressant Effects and Next-Day Impairment:Tell patients that flurazepam can cause next-day impairment, even in the absence of symptoms. Caution patients against driving or engaging in other hazardous activities or activities requiring complete mental alertness when using flurazepam. Tell patients that daytime impairment may persist for several days following discontinuation of flurazepam. Advise patients that increased drowsiness and decreased consciousness may increase the risk of falls in some patients [see *Warnings and Precautions* (5.4)].

Abnormal Thinking and Behavior Change:Instruct patients that sedative hypnotics can cause abnormal thinking and behavior change, including “sleep-driving” and other complex behaviors while not being fully awake (preparing and eating food, making phone calls, or having sex). Tell patients to call you immediately if they develop any of these symptoms [see *Warnings and Precautions* (5.7)].

Severe Allergic Reactions:Inform patients that severe allergic reactions can occur from flurazepam. Describe the signs/symptoms of these reactions and advise patients to seek medical attention immediately if these occur.

Worsening of Depression:Tell patients that flurazepam can worsen depression, and to immediately report any suicidal thoughts [see *Warnings and Precautions* (5.8)].

Alcohol and Other Drugs:Ask patients about alcohol consumption, medicines they are taking now, and drugs they may be taking without a prescription. Advise patients that alcohol generally should not be used during treatment with flurazepam.

Pregnancy:Advise pregnant females that use flurazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns [see *Warnings and Precautions* (5.9), *Use in Specific Populations* (8.1)] . Instruct patients to inform their healthcare provider if they are pregnant.

Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to flurazepam during pregnancy [see *Use in Specific Populations* (8.1)].

Lactation

Advise patients that breastfeeding is not recommended during treatment with flurazepam [see *Use in Specific Populations* (8.2)] .

Manufactured for:

Chartwell RX, LLC.

Congers, NY 10920

Revised: 12/2023

L71652

Print Medication Guides at: www.chartwellpharma.com/medguides

Print Medication Guides at: www.chartwellpharma.com/medguides

Medication Guide
Flurazepam Hydrochloride Capsules, USP
(flur az' e pam hye" droe klor' ide)



What is the most important information I should know about flurazepam hydrochloride capsules?

- **Flurazepam hydrochloride capsules are a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death.** Get emergency help right away if any of the following happens:
 - shallow or slowed breathing
 - breathing stops (which may lead to the heart stopping)
 - excessive sleepiness (sedation).

Do not drive or operate heavy machinery until you know how taking flurazepam hydrochloride capsules with opioids affect you.

- **Risk of abuse, misuse, and addiction.** There is a risk of abuse, misuse, and addiction with benzodiazepines, including flurazepam hydrochloride capsules, which can lead to overdose and serious side effects including coma and death.
 - **Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including flurazepam hydrochloride capsules.** These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. **Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects.**
 - **You can develop an addiction even if you take flurazepam hydrochloride capsules exactly as prescribed by your healthcare provider.**
 - **Take flurazepam hydrochloride capsules exactly as your healthcare provider prescribed.**
 - Do not share your flurazepam hydrochloride capsules with other people.
 - Keep flurazepam hydrochloride capsules in a safe place and away from children.
- **Physical dependence and withdrawal reactions.** Flurazepam hydrochloride capsules can cause physical dependence and withdrawal reactions, especially if you continue to take flurazepam hydrochloride capsules for several days to several weeks.
 - **Do not suddenly stop taking flurazepam hydrochloride capsules.** Stopping flurazepam hydrochloride capsules suddenly can cause serious and life-threatening side effects, including unusual movements, responses, or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. **Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms.**
 - **Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than 12 months,** including anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and

ringing in your ears.

- Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction.
- Do not take more flurazepam hydrochloride capsules than prescribed or take flurazepam hydrochloride capsules for longer than prescribed.
- After taking flurazepam hydrochloride capsules, you may get up out of bed while not being fully awake and do an activity that you do not know you are doing. The next morning, you may not remember that you did anything during the night. You have a higher chance for doing these activities if you drink alcohol or take other medicines that make you sleepy with flurazepam hydrochloride capsules. Reported activities include:
 - driving a car (“sleep-driving”)
 - making and eating food
 - talking on the phone
 - having sex
 - sleep-walking

Call your healthcare provider right away if you find out that you have done any of the above activities after taking flurazepam hydrochloride capsules.

What are flurazepam hydrochloride capsules?

- Flurazepam hydrochloride capsules are a prescription medicine used to treat certain types of insomnia including difficulty falling asleep, waking up often during the night, or waking up early in the morning.
- **Flurazepam hydrochloride is a federal controlled substance (C-IV) because it contains flurazepam that can be abused or lead to dependence.** Keep in a safe place to prevent misuse and abuse. Selling or giving away flurazepam hydrochloride capsules may harm others, and is against the law. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines or street drugs.
- It is not known if flurazepam hydrochloride capsules are safe and effective in children.

Do not take flurazepam hydrochloride capsules if you:

- are allergic to flurazepam hydrochloride, other benzodiazepines, or any of the ingredients in flurazepam hydrochloride capsules. See the end of this Medication Guide for a complete list of ingredients in flurazepam hydrochloride capsules. Symptoms of a serious allergic reaction can include:
 - swelling of your face, lips, and throat that may cause difficulty breathing or swallowing
 - nausea and vomiting

Before you take flurazepam hydrochloride capsules, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of depression, mental illness or, suicidal thoughts
- have a history of drug or alcohol abuse or addiction
- are pregnant or planning to become pregnant.
 - Taking Flurazepam hydrochloride late in pregnancy may cause your baby to have symptoms of sedation (breathing problems, sluggishness, low muscle tone), and/or withdrawal symptoms (jitteriness, irritability, restlessness, shaking, excessive crying, feeding problems).

- Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Flurazepam hydrochloride.
- There is a pregnancy registry for women who take Flurazepam hydrochloride during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. If you become pregnant during treatment with Flurazepam hydrochloride, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications. You can register by calling 1-866-961-2388 or visiting <https://womensmentalhealth.org/pregnancyregistry/>.
- are breastfeeding, or plan to breastfeed.
 - Talk to your healthcare provider about the best way to feed your baby if you take flurazepam hydrochloride capsules.
 - Breastfeeding is not recommended during treatment with Flurazepam hydrochloride.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking flurazepam hydrochloride capsules with certain other medicines can cause side effects or affect how well flurazepam hydrochloride capsules or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. Do not take flurazepam hydrochloride capsules with other medicines that can make you sleepy unless your healthcare provider tells you to.

How should I take flurazepam hydrochloride capsules?

- **See “What is the most important information I should know about flurazepam hydrochloride capsules?”**
- Take flurazepam hydrochloride capsules exactly as your healthcare provider tells you to take it.
- Take flurazepam hydrochloride capsules right before you get into bed.
- Do not take flurazepam hydrochloride capsules unless you are able to get a full night’s sleep before you must be active again.
- If you take too many flurazepam hydrochloride capsules, get emergency treatment right away.

What are the possible side effects of flurazepam hydrochloride capsules?

Flurazepam hydrochloride capsules may cause serious side effects, including:

- **See “What is the most important information I should know about flurazepam hydrochloride capsules?”**
- **Other conditions.** Call your healthcare provider if your insomnia worsens or is not better within 7 to 10 days. This may mean that there is another condition causing your sleep problem.
- **Severe allergic reactions.** Symptoms include swelling of the tongue or throat, and trouble breathing. Other symptoms may include nausea and vomiting. Get emergency medical help right away if you have these symptoms after taking flurazepam hydrochloride capsules.
- **Abnormal thoughts and behavior.** Symptoms include more outgoing or aggressive behavior than normal, confusion, agitation, hallucinations, worsening of depression, and suicidal thoughts.
- **Flurazepam hydrochloride capsules can make you sleepy or dizzy and can slow your thinking and motor skills.**

- Do not drive, operate heavy machinery, or do other dangerous activities until you know how flurazepam hydrochloride capsules affect you.
- Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking flurazepam hydrochloride capsules without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, flurazepam hydrochloride capsules may make your sleepiness or dizziness much worse.
- **Depression.** Pre-existing depression may emerge or worsen during use of benzodiazepines including flurazepam hydrochloride capsules.

The most common side effects of flurazepam hydrochloride capsules include:

- dizziness
- light-headedness
- loss of coordination
- drowsiness
- staggering
- falling

These are not all the possible side effects of flurazepam hydrochloride capsules. **Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800- FDA-1088.**

How should I store flurazepam hydrochloride capsules?

- Store at 20° to 25°C (68° to 77°F).
- Keep flurazepam hydrochloride capsules in a tightly closed container and out of the light.
- **Keep flurazepam hydrochloride capsules and all medicines out of the reach of children.**

General information about the safe and effective use of flurazepam hydrochloride capsules.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use flurazepam hydrochloride capsules for a condition for which it was not prescribed. Do not give flurazepam hydrochloride capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about flurazepam hydrochloride capsules that is written for healthcare professionals.

What are the ingredients in flurazepam hydrochloride capsules?

Active Ingredient: flurazepam hydrochloride

Inactive Ingredients: Anhydrous lactose, colloidal silicon dioxide, gelatin, FD&C Blue #1, FD&C Red #3, mannitol, magnesium stearate, talc, and titanium dioxide.

Additionally, capsule shells of 15 mg and 30 mg are imprinted with black pharmaceutical ink. The compositions of the black pharmaceutical ink are black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution.

Manufactured for:

Chartwell RX, LLC.
Congers, NY 10920

Revised: 09/2023

L71653

If you would like more information, call **Chartwell RX, LLC. at 1-845-232-1683.**

This Medication Guide has been approved by the U.S. Food and Drug Administration.

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL

Flurazepam Hydrochloride Capsules, USP CIV - 15 mg - NDC-62135-736-30 - Bottle Label

NDC 62135-736-30

Flurazepam **CIV**
Hydrochloride
Capsules, USP

15 mg

Rx Only
30 Capsules

Chartwell Rx

Each Capsule Contains:
Flurazepam HCl, USP15mg

Dispense in a tight, light-resistant container as defined in USP.

Usual Dosage: See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

PHARMACIST: Dispense Medication Guide provided separately to each patient.

Print Medication Guides at:
www.chartwellpharma.com/medguides
Manufactured For: Chartwell RX, LLC.
Congers, NY 10920

GTIN 00362135736309 L71853 REV. 01 12/23

3 **6213573630** **9**

No Varnish

Flurazepam Hydrochloride Capsules, USP CIV - 15 mg - NDC-62135-736-90 - Bottle Label

NDC 62135-736-90

Flurazepam **CIV**
Hydrochloride
Capsules, USP

15 mg

PHARMACIST: Dispense Medication Guide provided separately to each patient.

Print Medication Guides at:
www.chartwellpharma.com/medguides

Rx Only
90 Capsules

Chartwell Rx

Each Capsule Contains:
Flurazepam HCl, USP15mg

Dispense in a tight, light-resistant container as defined in USP.

Usual Dosage: See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured For: Chartwell RX, LLC.
Congers, NY 10920

GTIN 00362135736903 L71650 REV. 01 08/23

3 **6213573690** **3**

No Varnish

Flurazepam Hydrochloride Capsules, USP CIV - 30 mg - NDC-62135-737-30 - Bottle Label

NDC 62135-737-30

Flurazepam

Hydrochloride

Capsules, USP

30 mg

Rx Only

30 Capsules

Chartwell Rx

Each Capsule Contains:

Flurazepam HCl, USP.....30 mg

Dispense in a tight, light-resistant container as defined in USP.

Usual Dosage: See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].


KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

PHARMACIST: Dispense Medication Guide separately to each patient.

Print Medication Guides at: www.chartwellpharma.com/medguides

Manufactured For: Chartwell RX, LLC, Congers, NY 10920

GTIN 00362135737306 L71854 REV.01 12/23



N 3

6213573730

6

No Varnish

Flurazepam Hydrochloride Capsules, USP CIV - 30 mg - NDC-62135-737-90 - Bottle Label

NDC 62135-737-90

Flurazepam

Hydrochloride

Capsules, USP

30 mg

Rx Only

90 Capsules

Chartwell Rx

PHARMACIST: Dispense Medication Guide provided separately to each patient.

Print Medication Guides at: www.chartwellpharma.com/medguides

Each Capsule Contains:

Flurazepam HCl, USP.....30 mg

Dispense in a tight, light-resistant container as defined in USP.

Usual Dosage: See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured For: Chartwell RX, LLC, Congers, NY 10920

GTIN 00362135737900 L71651 REV.01 08/23



N 3

6213573790

0

No Varnish

FLURAZEPAM HYDROCHLORIDE

flurazepam hydrochloride capsule

Product Information

| | | | |
|-------------------------|-------------------------|--------------------|---------------|
| Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:62135-736 |
| Route of Administration | ORAL | DEA Schedule | CIV |

Active Ingredient/Active Moiety

| Ingredient Name | Basis of Strength | Strength |
|--|--------------------------|----------|
| FLURAZEPAM HYDROCHLORIDE (UNII: 756RDM536M) (FLURAZEPAM - UNII:IHP475989U) | FLURAZEPAM HYDROCHLORIDE | 15 mg |

| Inactive Ingredients | |
|--|----------|
| Ingredient Name | Strength |
| ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK) | |
| SILICON DIOXIDE (UNII: ETJ7Z6XBU4) | |
| FD&C BLUE NO. 1 (UNII: H3R47K3TBD) | |
| FD&C RED NO. 3 (UNII: PN2ZH5LOQY) | |
| GELATIN, UNSPECIFIED (UNII: 2G86QN327L) | |
| MANNITOL (UNII: 3OWL53L36A) | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | |
| TALC (UNII: 7SEV7J4R1U) | |
| TITANIUM DIOXIDE (UNII: 15FIX9V2JP) | |
| FERROSO FERRIC OXIDE (UNII: XM0M87F357) | |
| BUTYL ALCOHOL (UNII: 8PJ61P6TS3) | |
| ALCOHOL (UNII: 3K9958V90M) | |
| ISOPROPYL ALCOHOL (UNII: ND2M416302) | |
| POTASSIUM HYDROXIDE (UNII: WZH3C48M4T) | |
| PROPYLENE GLYCOL (UNII: 6DC9Q167V3) | |
| SHELLAC (UNII: 46N107B71O) | |
| AMMONIA (UNII: 5138Q19F1X) | |
| WATER (UNII: 059QF0KO0R) | |

| Product Characteristics | | | |
|-------------------------|---|---------------------|----------|
| Color | blue (cap) , white (body) | Score | no score |
| Shape | CAPSULE (Size #2 hard gelatin capsules) | Size | 18mm |
| Flavor | | Imprint Code | CE;28 |
| Contains | | | |

| Packaging | | | | |
|-----------|------------------|---|----------------------|--------------------|
| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
| 1 | NDC:62135-736-30 | 30 in 1 BOTTLE; Type 0: Not a Combination Product | 12/19/2023 | |
| 2 | NDC:62135-736-90 | 90 in 1 BOTTLE; Type 0: Not a Combination Product | 09/08/2023 | |

| Marketing Information | | | |
|-----------------------|--|----------------------|--------------------|
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA072368 | 03/30/1989 | |

FLURAZEPAM HYDROCHLORIDE

flurazepam hydrochloride capsule

Product Information

| | | | | |
|--|---|---|----------------------|--------------------|
| Product Type | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:62135-737 | |
| Route of Administration | ORAL | DEA Schedule | CIV | |
| | | | | |
| Active Ingredient/Active Moiety | | | | |
| Ingredient Name | | Basis of Strength | Strength | |
| FLURAZEPAM HYDROCHLORIDE (UNII: 756RDM536M) (FLURAZEPAM - UNII:IHP475989U) | | FLURAZ EPAM HYDROCHLORIDE | 30 mg | |
| | | | | |
| Inactive Ingredients | | | | |
| Ingredient Name | | | Strength | |
| ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK) | | | | |
| SILICON DIOXIDE (UNII: ETJ7Z6XBU4) | | | | |
| FD&C BLUE NO. 1 (UNII: H3R47K3TBD) | | | | |
| FD&C RED NO. 3 (UNII: PN2ZH5LOQY) | | | | |
| GELATIN, UNSPECIFIED (UNII: 2G86QN327L) | | | | |
| MANNITOL (UNII: 3OWL53L36A) | | | | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | | | | |
| TALC (UNII: 7SEV7J4R1U) | | | | |
| TITANIUM DIOXIDE (UNII: 15FIX9V2JP) | | | | |
| FERROSOFERRIC OXIDE (UNII: XM0M87F357) | | | | |
| BUTYL ALCOHOL (UNII: 8PJ61P6TS3) | | | | |
| ALCOHOL (UNII: 3K9958V90M) | | | | |
| ISOPROPYL ALCOHOL (UNII: ND2M416302) | | | | |
| POTASSIUM HYDROXIDE (UNII: WZH3C48M4T) | | | | |
| PROPYLENE GLYCOL (UNII: 6DC9Q167V3) | | | | |
| SHELLAC (UNII: 46N107B71O) | | | | |
| AMMONIA (UNII: 5138Q19F1X) | | | | |
| WATER (UNII: 059QF0KO0R) | | | | |
| | | | | |
| Product Characteristics | | | | |
| Color | blue (cap) , white (body) | Score | no score | |
| Shape | CAPSULE (Size #2 hard gelatin capsules) | Size | 18mm | |
| Flavor | | Imprint Code | CE;29 | |
| Contains | | | | |
| | | | | |
| Packaging | | | | |
| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
| 1 | NDC:62135-737-30 | 30 in 1 BOTTLE; Type 0: Not a Combination Product | 12/19/2023 | |
| 2 | NDC:62135-737-90 | 90 in 1 BOTTLE; Type 0: Not a Combination Product | 09/08/2023 | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| ANDA | ANDA072369 | 03/30/1989 | |

Labeler - Chartwell RX, LLC (079394054)

Revised: 10/2024

Chartwell RX, LLC